Oncolytics Announces Reovirus Research to be Presented at AACR Annual Meeting
News Mar 30, 2012
Oncolytics Biotech Inc. has announced that abstracts of preclinical research on reovirus (REOLYSIN®) are available on the American Association for Cancer Research (AACR) website at www.aacr.org.
The research is scheduled to be presented at the 2012 AACR Annual Meeting in Chicago, IL, which takes place from March 31 to April 4, 2012.
"We are delighted to see that the research community has been embracing preclinical research utilizing reovirus," said Dr. Matt Coffey, Chief Operating Officer of Oncolytics.
Dr. Coffey continued, "This research helps us to continue to refine our understanding of REOLYSIN's mechanism of action, its suitability for combination with other treatment modalities and its potential for application to a growing range of potential cancer indications."
The first abstract, entitled "Reovirus (REOLYSIN) as a potential therapy for malignant peripheral nerve sheath tumors," covers preclinical work in malignant peripheral nerve sheath tumors (MPNST), a rare form of soft tissue sarcoma.
The results show that MPNST-derived cell lines including sporadic MPNST without active Ras were efficiently transduced, promoted virus replication and were killed by the oncolytic reovirus. The poster is scheduled to be presented on Monday, April 2, 2012.
The second abstract, entitled "REOLYSIN: A novel reovirus-based agent that induces endoplasmic reticular stress in RAS-activated pancreatic cancer," covers preclinical work done to better understand the mechanisms associated with the synergies in this co-treatment approach.
The results demonstrate that the abnormal protein accumulation induced by REOLYSIN and bortezomib promotes heightened ER stress and apoptosis in pancreatic cancer cells. The poster is scheduled to be presented on Monday, April 2, 2012.
The third abstract, entitled "Oncolytic reovirus synergizes with bortezomib and dexamethasone in overcoming therapy resistance of multiple myeloma," covers preclinical work done in therapy resistant multiple myeloma (MM) cell lines.
The investigators noted that highly synergistic cytotoxicity was observed with reovirus and bortezomib in both reovirus and drug resistant cell lines OPM2 and KMS-11 at all drug combination ratios.
Dexamethasone and reovirus treatment induced synergy in OPM2 cells. The poster is scheduled to be presented on Tuesday, April 3, 2012.
The fourth abstract, entitled "Serum regulates reovirus-mediated cytopathy in K-Ras activated colorectal cancer and intestinal epithelial cell lines," covers the use of isogenic human-derived colorectal cancer cell lines that differ only by the presence of mutant Kras and normal rat intestinal epithelial cells (IEC) with inducible Kras to evaluate whether the presence of oncogenic Kras alters the sensitivity of colon cancer cells to reovirus.
The investigators demonstrated that the activity of reovirus was observed in all cell lines studied. Reduction in cell variability was greater in Kras-mutant HCT116 compared to WT Hke3 cells.
Consistently, induction of Kras in IEC cells increased the potency of reovirus. The poster is scheduled to be presented on Tuesday, April 3, 2012.
The fifth abstract, entitled "Mammalian orthoreovirus downregulates HIF-1a in hypoxic prostate tumor cells via RACK1-mediated proteasomal degradation and translational inhibition," was added as a late-breaking abstract. The poster is scheduled to be presented on Tuesday April 3, 2012.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018